^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YPN-005

    i
    Other names: YPN-005, YPN 005, YPN005
    Company:
    KT&G Corp
    Drug class:
    CDK7 inhibitor
    Related drugs:
    1year
    Antileukemic effect of cyclin-dependent kinase 7 inhibitor; YPN-005 combined with FLT3 inhibitor in FMS-tyrosine kinase 3 -mutated acute myeloid leukemia (ICKSH 2023)
    FLT3-TKIs include midostaurin, gilteritinib, and quizartinib. These results provide preclinical evidence of combined treatment of YPN-005 and FLT3 inhibitor for therapeutic strategies for FLT3-mutated AML. Keyword : FLT3-ITD, CDK7 inhibitor, Mitochondrial dysfunction, Apoptosis
    PARP Biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • CDK7 (Cyclin Dependent Kinase 7) • ANXA5 (Annexin A5)
    |
    FLT3-ITD mutation • FLT3 mutation • MYC expression • MCL1 expression • FLT3-ITD expression
    |
    Xospata (gilteritinib) • Rydapt (midostaurin) • Vanflyta (quizartinib) • YPN-005
    over1year
    Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia. (PubMed, Heliyon)
    Phosphorylated FLT3/Signal transducer and activator of transcription 5 (STAT5) was decreased and FLT3/STAT5 was downregulated with YPN-005 treatment. Our data suggest that YPN-005 has a role in treating AML by suppressing c-MYC and FLT3.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    FLT3-ITD mutation • MYC expression
    |
    YPN-005